Phio Pharmaceuticals Corp.

Trading Plans

During the three months ended December 31, 2024, no director or officer of the Company adopted orterminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.

Employment Agreement Amendment

On March 25, 2025, we and Robert Bitterman entered into an amendment (the “Amendment”) to the existing employment agreement with Mr. Bitterman, dated February 20, 2023 (the “Existing Employment Agreement”). The Amendment amends the severance provision in the Existing Employment Agreement to provide that, in addition to the (3) months of continued payment of Mr. Bitterman’s then-current base salary that Mr. Bitterman is entitled to under the Existing Employment Agreement in certain circumstances then, in such cases, he shall also be entitled to an additional one (1) month of continued payment of his then-current base salary for each completed year of service with the Company, not to exceed a total severance of six (6) months. Except as set forth in the Amendment, all other terms and conditions of the Existing Employment Agreement remain in full force and effect, and descriptions of such terms and conditions are included within Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q filed on May 11, 2023, which is incorporated herein by reference. The description of the Amendment is a summary only, and is qualified in its entirety by reference to the Amendment, which is attached hereto as Exhibit 10.30 and incorporated herein by reference.